TW202304957A - Kv1.3阻斷劑 - Google Patents

Kv1.3阻斷劑 Download PDF

Info

Publication number
TW202304957A
TW202304957A TW111110743A TW111110743A TW202304957A TW 202304957 A TW202304957 A TW 202304957A TW 111110743 A TW111110743 A TW 111110743A TW 111110743 A TW111110743 A TW 111110743A TW 202304957 A TW202304957 A TW 202304957A
Authority
TW
Taiwan
Prior art keywords
cdata
nle
seq
amino acid
xaa
Prior art date
Application number
TW111110743A
Other languages
English (en)
Chinese (zh)
Inventor
翰維克 費雪 馬司
Original Assignee
丹麥商西蘭製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 丹麥商西蘭製藥公司 filed Critical 丹麥商西蘭製藥公司
Publication of TW202304957A publication Critical patent/TW202304957A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111110743A 2021-03-23 2022-03-23 Kv1.3阻斷劑 TW202304957A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21164384 2021-03-23
EP21164384.6 2021-03-23
EP21213431 2021-12-09
EP21213431.6 2021-12-09

Publications (1)

Publication Number Publication Date
TW202304957A true TW202304957A (zh) 2023-02-01

Family

ID=80952156

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111110743A TW202304957A (zh) 2021-03-23 2022-03-23 Kv1.3阻斷劑

Country Status (12)

Country Link
US (1) US20240182531A1 (enExample)
EP (1) EP4314024A1 (enExample)
JP (1) JP2024511449A (enExample)
KR (1) KR20230159403A (enExample)
AU (1) AU2022245193A1 (enExample)
BR (1) BR112023019022A2 (enExample)
CA (1) CA3208713A1 (enExample)
CL (1) CL2023002590A1 (enExample)
IL (1) IL305219A (enExample)
MX (1) MX2023010930A (enExample)
TW (1) TW202304957A (enExample)
WO (1) WO2022200374A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4604984A1 (en) * 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8429751B2 (en) 2009-03-13 2013-04-23 Trustwave Holdings, Inc. Method and apparatus for phishing and leeching vulnerability detection
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
JP2016527250A (ja) 2013-07-22 2016-09-08 キネタ ワン リミテッド ライアビリティ カンパニーＫｉｎｅｔａ Ｏｎｅ，Ｌｌｃ 毒素系治療用ペプチド及びその医薬組成物の眼科的使用
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
EP4031162A1 (en) * 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers

Also Published As

Publication number Publication date
US20240182531A1 (en) 2024-06-06
CA3208713A1 (en) 2022-09-29
EP4314024A1 (en) 2024-02-07
JP2024511449A (ja) 2024-03-13
CL2023002590A1 (es) 2024-03-15
AU2022245193A1 (en) 2023-09-07
IL305219A (en) 2023-10-01
BR112023019022A2 (pt) 2023-10-17
WO2022200374A1 (en) 2022-09-29
KR20230159403A (ko) 2023-11-21
MX2023010930A (es) 2023-09-28

Similar Documents

Publication Publication Date Title
US11395847B2 (en) Acylated GLP-1/GLP-2 dual agonists
JP7703520B2 (ja) Ｋｖ１．３遮断剤
AU2007319066B2 (en) Selective glucagon-like-peptide-2 (GLP-2) analogues
WO2018104558A1 (en) Acylated glp-1/glp-2 dual agonists
WO2018103868A1 (en) Acylated glp-1/glp-2 dual agonists
KR20230159403A (ko) Kv1.3 차단제
RU2825633C1 (ru) БЛОКАТОРЫ Kv1.3
CN117255798A (zh) Kv1.3阻断剂
KR20250089536A (ko) 억제제
WO2024029242A1 (ja) 新規ｌｒｐ１結合ペプチド
HK40111792A (en) Acylated glp-1/glp-2 dual agonists